Indication
For the treatment of adult patients with early primary progressive multiple sclerosis (PPMS) in terms of disease duration and level of disability, and with imaging features characteristic of inflammatory activity.
Medicine details
- Medicine name:
- ocrelizumab (Ocrevus)
- SMC ID:
- SMC2223
- Pharmaceutical company
- Roche
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Full
- Status
- Publication due date:
- Q1 2020
- SMC meeting date:
- Q4 2019
- Patient group submission deadline:
- 30 September 2019